The MSU-CHM Office of Research is offering a number of research scholarships in various areas, including oncology, neurology, breast cancer and innovation. These awards are for CHM students in good standing.
The application deadline for all awards is Tuesday, Feb 18, 2025 at 11:59pm.
A total of 13 awards will be given.
See below for more information.
----
NOTE: These scholarship awards require students to have identified a research mentor and prepare a research proposal and plan as well as a Presentation/Publication plan.
Please see this link: Sample Proposal and Plan for a sample research proposal and plan.These open scholarship awards are:
Oncology Scholarships - Four (4) students will be selected to receive this award for research related to cancer. The oncology scholarships are funded by the Helen and Verne Beilfuss Endowment and the Barbara J. Guthrie/Gale Sanborn Endowment Fund
Breast Cancer Scholarship - One (1) student will be selected to receive this award for research into breast cancer. The Breast Cancer research scholarship is funded by the Maureen K. Burrill Memorial Fund for Breast Cancer Research.
Innovation Scholarships - Five (5) students will be selected to receive this award for innovative research in any field. The Innovation scholarships are funded by the CHM Endowed Fund for Innovation
Neurology Scholarships - One (1) student will be selected to receive this award for research in neurology/neurosciences. These awards are funded by the Keenan Joseph Marshall Endowed Research Fund.
For students taking a year off for research:
Oncology Year-off Research Supplement - One (1) student will be selected to receive this award for research related to cancer. This award is funded by the Helen and Verne Beilfuss Endowment
Mentored Research Opportunity - in person research at the Grand Rapids Research Center:
Mentored Cancer Research Scholarship - One student will be selected to conduct research in the laboratory of Dr. Jennifer Klomp. This is an in person research experience in Summer 2025 with a time commitment of 8+ weeks. Dr. Klomp's laboratory is located in the Grand Rapids Research Center.
Description of Mentored Cancer Research Scholarship
https://medicine.chm.msu.edu/research-program/Klomp%20Lab/index.html
Dr. Jennifer E. Klomp is an assistant professor in the Department of Medicine at the Michigan State University College of Human Medicine. Her research focuses on understanding how aberrant kinase signaling downstream of oncogenic KRAS contributes to cancer cell development, growth, maintenance, migration, and acquired resistance.
Project Description: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer deaths in the United States and is characterized by a 95% rate of mutational activation of the KRAS oncogene. We currently are focused on studying serine/threonine kinases ERK1/2 (ERK) in PDAC because of the nearly ubiquitous addiction of PDAC to oncogenic KRAS and the importance of ERK in driving that dependence. The scholarship student’s research project would be focused on understanding how nuclear versus cytoplasmic populations of ERK activity: 1) contribute to resistance of clinically relevant KRAS/RAS inhibitors, and 2) how they drive oncogenic KRAS signaling in PDAC. To do so they will utilize novel ERK biosensors and constructs in human PDAC cell lines.
The Mentored Cancer Research Scholarhsip is funded by the Helen and Verne Beilfuss Endowment.
To apply: Access the CHM Office of Research InfoReady site here: https://chm-studentresearch.infoready4.com/. Log in with your MSU NetID.
Select:
"2025 CHM Office of Research Scholarship Competition" from the menu for all awards except the Mentored Cancer Research Scholarship.
"2025 Mentored Cancer Research Scholarship" from the menu for the Mentored Cancer Research Scholarship in Dr. Jennifer Klomp's lab.
Applications will require submission of a CV. All except the Mentored Cancer Research Scholarship will require a Research Proposal and Plan (see sample here) and a Presentation/Publication plan.
Students will be notified of award decisions by April 1, 2025.
